Hormone Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Hormone Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Predicting Recurrence in HR+/HER2- Early Breast Cancer
This clinical trial update from Shengjing Hospital describes a study aiming to predict recurrence in early-stage HR+/HER2- breast cancer, wi…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer [Phase 1, Phase 2]
This clinical trials update reports a Phase 1/2 study evaluating EP0062 as both a monotherapy and in combination therapy for advanced or met…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer [NA]
This ClinicalTrials.gov entry describes an ongoing study evaluating brain MRI screening in patients with breast cancer, including HER2-posit…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer [Phase 2]
This Clinical Trials update describes the I-SPY TRIAL, a Phase 2 neoadjuvant breast cancer study using personalized adaptive agents; recruit…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer
The entry reports a real-world clinical trial evaluating the Endopredict prognostic test in early HR-positive, HER2-negative breast cancer; …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-12Clinical Trial Update: Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients [Phase 2]
Phase 2 neoadjuvant trial comparing chemotherapy versus letrozole plus abemaciclib in HR+/HER2- high/intermediate risk early breast cancer; …
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer [Phase 2]
This is a Phase 2 clinical trial update for a combination of anastrozole, fulvestrant, and abemaciclib in HR-positive, HER2-negative metasta…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer [Phase 2]
This clinical trial update describes a Phase II study evaluating HLX43 for efficacy and safety in patients with hormone receptor-positive, H…
-
CLINICAL_TRIALS trial_result · 2026-03-06Clinical Trial Update: Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer
A clinical trial investigating adherence to aromatase inhibitors with or without abemaciclib in early-stage HER2-negative breast cancer is c…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib [Phase 2]
A Phase 2 pragmatic trial in hormone receptor-positive, HER2-negative early breast cancer is testing optimized neoadjuvant therapy and poten…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
A study led by Tempus AI is evaluating minimal residual disease in breast cancer by longitudinal ctDNA profiling to track disease status acr…
-
CLINICAL_TRIALS trial_result · 2026-03-03Clinical Trial Update: Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) [Phase 2]
A Phase 2 ComboMATCH trial evaluating fulvestrant plus binimetinib for NF1-mutant, hormone receptor-positive metastatic breast cancer was te…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer [Phase 2]
This clinical trial update notes a single-arm Phase II study evaluating the combination of entinostat and oral paclitaxel for hormone recept…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.
This completed clinical trial update describes real-world treatment patterns and clinical outcomes for patients with HR+/HER2- advanced/meta…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer [Phase 3]
Phase 3 trial evaluating metronomic capecitabine plus an aromatase inhibitor as first-line therapy for HR-positive, HER2-negative metastatic…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment [Phase 3]
A Phase III clinical trial is evaluating capivasertib plus standard endocrine therapy in HR-positive, HER2-negative advanced breast cancer t…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Rash & Diarrhea Prophylaxis With Capivasertib [Phase 2]
Phase 2 clinical trial evaluating rash and diarrhea prophylaxis with capivasertib in metastatic hormone receptor-positive, HER2-negative bre…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors [Phase 1, Phase 2]
This is a Phase 1/2 clinical trial evaluating GVV858 as a single agent or in combination with endocrine therapy for hormone receptor-positiv…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating Efti in patients with hormone receptor-positive, HER2-negative breast cancer; not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating radiation therapy combined with pembrolizumab and olaparib (or other radiosensitizers) in women with …
-
CLINICAL_TRIALS trial_result · 2026-02-13Clinical Trial Update: ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer [Phase 2]
A Phase 2 trial evaluating ARX788 for HER2-low breast cancer (locally advanced unresectable or metastatic) is currently not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer [Phase 1]
A Phase 1 clinical trial evaluating abemaciclib in combination with radiation therapy for metastatic breast cancer; the study is currently r…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer
A recruiting clinical trial evaluating how endocrine therapy, menstrual cycle phases, PAM50 subtype, and Ki67 influence treatment decisions …
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) [Phase 3]
A Phase 3 clinical trial update indicates Gedatolisib plus Fulvestrant, with or without Palbociclib, is active but not recruiting for advanc…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer [Phase 2]
Clinical trial update indicates a Phase 2 neoadjuvant study of iParomlimab and Tuvonralimab (QL1706) in hormone receptor-positive, HER2-nega…